PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (HGH SUPPORT)
DRUG NAME: IBUTAMOREN (MK-677)

  • FDA Safety Data Sheet not available

  • Sinha DK. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 [PubMed Link]

  • Sigalos J. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 [PubMed Link]

  • Liu H. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun. 2021 [PubMed Link]

  • Murphy MG. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998 [PubMed Link]

  • Cardaci TD. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Exp Physiol. 2022 [PubMed Link]

  • Patchett AA. Orally active growth hormone secretagogues. Pharm Biotechnol. 1998 [PubMed Link] 

  • Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005 [PubMed Link]

  • Svensson J. Growth hormone secretagogues as therapeutic agents. Growth Horm IGF Res. 1999 [PubMed Link]

  • Robinson IC. Hypothalamic targets for growth hormone secretagogues. Acta Paediatr Suppl. 1997 [PubMed Link]

  • Micic D. Growth hormone secretagogues: the clinical future. Horm Res. 1999 [PubMed Link]

  • Ghigo E. Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm Res. 1999 [PubMed Link]

  • Smith RG. Growth hormone releasing substances: types and their receptors. Horm Res. 1999 [PubMed Link]

  • Svensson JA. Clinical and experimental effects of growth hormone secretagogues on various organ systems. Horm Res. 1999 [PubMed Link]

  • Smith RG. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997 [PubMed Link]

  • Fuh VL. Growth hormone secretagogues: mechanism of action and use in aging. Growth Horm IGF Res. 1998 [PubMed Link]

  • Gaugg M. Rejuvenation in older adults receiving oral ghrelin. Ann Intern Med. 2009 [PubMed Link]

  • Papotti M. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000 [PubMed Link]

  • Copinschi G. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 [PubMed Link]

  • Patchett AAl. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 [PubMed Link]

  • Nass R. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008 [PubMed Link]